Compare Brookfield Infrastructure Partners LP (BIP) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs Crispr Therapeutics AG — how do they compare? Brookfield Infrastructure Partners LP trades at $39.54 (market cap $18.10B), while Crispr Therapeutics AG trades at $53.98 (market cap $5.23B). The key difference: Brookfield Infrastructure Partners LP is far larger — about 3.5× Crispr Therapeutics AG's market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| BIP | CRSP | |
|---|---|---|
Market Cap | $18.10B | $5.23B |
Sector | Industrials | Health |
52-Week High | $42.62 | $76.78 |
52-Week Low | $29.81 | $44.34 |
Enterprise Value | $77.05B | $3.65B |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.45, up 3.87% today, with a bullish technical signal from moving averages. The company reported revenue of $23.10B in 2025 but has missed recent EPS estimates, with Q2 2026 actual EPS at -$0.07 versus a $0.16 expectation. Recent news highlights its dividend appeal and corporate simplification plans, while analyst consensus remains strongly positive with a $44.67 price target.
BIP offers a high dividend yield and attractive EV/EBITDA valuation, but faces risks from earnings misses and high debt. The stock's upside depends on execution of its infrastructure strategy and improved profitability. Investor sentiment is buoyed by institutional support and media coverage emphasizing long-term value, though near-term volatility may persist amid macroeconomic uncertainty.
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
